Summit Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
SMMT$17.83-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year Ended December 31, 2023 | Year Ended December 31, 2022 | |
|---|---|---|
| Revenue | $— | $705 |
| Operating expenses: | ||
| Research and development | 59,471 | 51,999 |
| General and administrative | 30,265 | 26,743 |
| In-process research and development | 520,915 | — |
| Impairment of intangible assets | — | 8,468 |
| Total operating expenses | 610,651 | 87,210 |
| Other operating income | 1,001 | 14,416 |
| Operating loss | (609,650) | (72,089) |
| Other expense, net | (5,278) | (6,693) |
| Loss before income tax | (614,928) | (78,782) |
| Net loss | $(614,928) | $(78,782) |
| Net loss per share: | ||
| Basic and diluted | $(0.99) | $(0.41) |
| Weighted average common shares outstanding: | ||
| Basic and diluted | 619,646,180 | 193,336,063 |
| Other comprehensive (loss) income: | ||
| Foreign currency translation adjustments | (172) | 304 |
| Reclassification of cumulative currency translation gain to other expense, net | (419) | — |
| Unrealized gain on short-term investments | 36 | — |
| Comprehensive loss | $(615,483) | $(78,478) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.